VKTX · Viking Therapeutics, Inc.
$34.79
-0.60 (-1.70%)
At close · Jul 24
Market Cap
$4.04B
Shares
116.11M
Viking Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Viking Therapeutics, Inc. (VKTX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$
−$15.77M
'22 Q3
22-10-26
·
$
−$19.56M
'22 Q4
23-02-08
·
$
−$19.53M
'23 Q1
23-04-26
·
$
−$19.23M
'23 Q2
23-07-26
·
$
−$22.53M
'23 Q3
23-10-25
·
$
−$24.61M
'23 Q4
24-02-07
·
$
−$27.36M
'24 Q1
24-04-24
·
$
−$22.25M
'24 Q2
24-07-24
·
$
−$24.94M
'24 Q3
24-10-23
·
$
−$35.42M
'24 Q4
25-02-05
·
$
−$45.63M
'25 Q1
25-04-23
·
$
−$65.56M
'25 Q2
25-07-23
·
$
−$90.79M
'25 Q3
25-10-22
·
$
−$157.66M
'25 Q4
26-02-11
LATEST
·
$
−$158.32M
'26 Q1
26-04-29
Earnings call
FY26 · Q2
2026-07-29
Viking Therapeutics Q2 2026 Earnings Call and Webcast
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Viking Therapeutics, Inc. Q1 FY2026 Earnings Call
Revenue
$
Diluted EPS
$-1.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
Viking Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
Subcutaneous VK2735 Phase III VANQUISH program
Manufacturing and supply chain (CordenPharma, auto-injector)
Amylin agonist pipeline expansion
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-22
Viking Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
VK2735 subcutaneous Phase III VANQUISH program
Oral VK2735 VENTURE-Oral Dosing Trial
Maintenance dosing study
Revenue
$
Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-23
Viking Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
VK2735 subcutaneous VANQUISH Phase III program
VK2735 oral formulation and Phase II results
Amylin receptor agonist program and IND filing
Revenue
$
Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Viking Therapeutics, Inc. Q1 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-05
Viking Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
VK2735 subcutaneous obesity program (VENTURE)
VK2735 oral tablet for obesity
Phase 3 planning for VK2735
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-23
Viking Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
VK2735 subcutaneous obesity program (VENTURE Phase 2)
VK2735 oral formulation
VK2809 NASH/fibrosis program (VOYAGE)
Revenue
$
Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Viking Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
VK2735 subcutaneous Phase 2 VENTURE trial
VK2809 NASH VOYAGE trial
Oral VK2735 formulation
Revenue
$
Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Viking Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
Subcutaneous VK2735 Phase II VENTURE results in obesity
VK2809 Phase IIb VOYAGE study in NASH
Oral VK2735 tablet formulation development
Revenue
$
Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-07
Viking Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
VK2735 obesity program (VENTURE Phase II)
VK2809 NASH program (VOYAGE)
VK2735 oral formulation Phase I
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Viking Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-26
Viking Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Viking Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Viking Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Viking Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Viking Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Viking Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-09
Viking Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Viking Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Viking Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Viking Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Viking Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Viking Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
Viking Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Viking Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts
CIK
1607678
CUSIP
92686J106
13F (30d)
73 filings
73 filers
Visit website
Investor relations